REalWorld Insights on the INitiation and Treatment Duration of ticagrEloR & Other Oral Antiplatelets in Patients With Acute Coronary Syndrome in Belgium/Luxembourg (REWINDER)

Trial Profile

REalWorld Insights on the INitiation and Treatment Duration of ticagrEloR & Other Oral Antiplatelets in Patients With Acute Coronary Syndrome in Belgium/Luxembourg (REWINDER)

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Feb 2016

At a glance

  • Drugs Ticagrelor (Primary) ; Clopidogrel; Prasugrel
  • Indications Acute coronary syndromes
  • Focus Therapeutic Use
  • Acronyms REWINDER
  • Sponsors AstraZeneca
  • Most Recent Events

    • 05 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Jan 2015 Planned End Date changed from 1 Dec 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.
    • 08 Jan 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top